Lumos has announced a follow-on contract with Aptatek Biosciences to advance the PheCheck™ in-home monitoring device for phenylketonuria (PKU). Read the ASX release: $LDX #LDX #Lumos #diagnostics #pointofcare #healthcare #innovation

Lumos has announced that BARDA has awarded US$6.2 million in non-dilutive funding to support a new U.S. paediatric study of our flagship FebriDx® test. Read the ASX release: $LDX #LDX #Lumos #diagnostics #pointofcare #pediatrics #healthcare #innovation

Annual Report | Lumos Diagnostics has today published its Annual Report for FY25. Click here to read the full report: $LDX #FDA #medicaldevice #pointofcare #invest #innovation #health #biotech #medtech #AMR

Analyst report | MST Access has updated coverage on Lumos after our CLIA waiver submission for FebriDx®, lifting valuation to A$0.22 and outlining the opportunities ahead. Read the full report: $LDX #LDX #Lumos #diagnostics #pointofcare #rapidtest #FebriDx

$LDX Update | Lumos Diagnostics has announced the completion of the clinical study and submission of its application to the U.S. FDA for CLIA waiver classification for FebriDx®. Read the ASX release: #LDX #Lumos #respiratoryhealth #pointofcare #diagnostics

$LDX | #Lumos has entered into a partnering agreement with US-based market access consultancy, PRO-spectus, to support the marketing, market access and reimbursement of its flagship point-of-care test, FebriDx®. Read the ASX release: #pointofcare #FebriDX

We’re live at #ADLM2025 in Chicago! Visit @Lumos_Dx at Booth 3651 connect with our team and learn more about FebriDx® and our end-to-end point-of-care diagnostic capabilities. $LDX #LDX #Lumos #pointofcare #diagnostics #rapidtest #medtech #FebriDx #healthcare #innovation

29-31 July | We’re heading to #ADLM2025 in Chicago next week. Visit @Lumos_Dx at Booth 3651 to see our reader platforms in action and meet the team behind FebriDx® and our full-service POC diagnostic capabilities. LDX #LDX #Lumos #ADLM2025 #pointofcare #diagnostics #rapidtest

REPLAY | #Lumos held an investor briefing yesterday outlining the transformational US$317 million distribution agreement with PHASE Scientific. If you missed it, here’s the replay: $LDX #LDX #pointofcare #diagnostics #FebriDx #healthcare #commercialisation.

$LDX | Lumos has today announced a binding A$5.0 million secured loan facility with major shareholders, Tenmile and Ryder Capital. Read the ASX release: #LDX #ASX #pointofcare #diagnostics #FebriDx #healthcare #commercialisation

Stockhead TV | In this interview #Lumos CEO Doug Ward discusses the significance of our exclusive distribution agreement with PHASE Scientific, and why they are the ideal partner for growing FebriDx's footprint in the US. Watch it now: $LDX #LDX #FebriDx.

#Lumos CEO Doug Ward spoke with Proactive presenter Fouad Haidar about the company’s exclusive US distribution agreement for FebriDx® with PHASE Scientific International Limited (PHASE Scientific). Take a look: .$LDX #LDX #pointofcare #rapidtest #ASX #deal.

$LDX DEAL | #Lumos Diagnostics has signed a transformational US distribution deal with PHASE Scientific for FebriDx® worth up to US$317m over six years. Read today's #ASX release: #innovation #biotech #healthcare #pointofcare

FebriDx® will be used as part of the University of Wollongong's OPTIMAS-GP Trial - a major $2.7 million antimicrobial stewardship study funded by the Australian Government's Medical Research Future Fund. Read the ASX release: #LDX #Lumos #FebriDx #AMR

Yesterday's news that #Lumos has reached a critical recruitment milestone in our CLIA Waiver study was featured in a special report in The Australian today. Read the full article: .$LDX #LDX #rapidtest #diagnostics #FebriDx #respiratoryhealth #healthcare.

#Lumos has announced that the Company has now successfully achieved 61 bacterial positive patients, representing 50% of the target of 120 bacterial positive patient results required for the study. Read the ASX release $LDX #LDX #rapidtest #diagnostics

#Lumos has received confirmation of Medicare reimbursement coverage for FebriDx from a sixth Medicare Administrative Contractors (MACs), CGS Administrators, retroactive from 1 May 2025. Read the ASX release: $LDX #LDX #rapidtest #diagnostics #healthcare

$LDX | This special report in The @australian details how #Lumos has achieved Medicare reimbursement from five of seven Medicare Administrative Contractors (MACs), representing more than 70% of total US Medicare payment coverage. Read the full article :

#Lumos is pleased to be working with WA-based @TeleMedVET to develop a point-of-care diagnostic solution for equine health monitoring. This partnership demonstrates our strategic approach to #diagnostic development to create fit-for-purpose solutions. $LDX

#Lumos has announced that it has received and shipped a purchase order for FebriDx® from iMedical, Inc. for US$126,000, representing its largest single purchase order since the test's launch. Read the ASX Release: .$LDX #LDX #diagnostics #healthcare